Bedinvetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Librela |
| AHFS/Drugs.com | Veterinary Use |
| License data |
|
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C6458H9972N1740O2014S44 |
| Molar mass | 145623.62 g·mol−1 |
Bedinvetmab, sold under the brand name Librela, is a fully canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs. Librela is sponsored by Zoetis.
Bedinvetmab was approved for medical use in the European Union in November 2020, and in the United States in May 2023. Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.